OakChart

Bolt Biotherapeutics Inc

BOLTHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

6.26-0.04 (-0.63%)
2026-11-11 22:59 CET
Market cap
12.14 USD m
Revenue, TTM
4.70 USD m
Net income, TTM
-28.74 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-16.44
P/E
-
Compare

Price

BOLT against its 20, 50 and 200-day averages
2050200missearnings
4.006.008.006.4M12.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BOLTclose 6.2620-day 5.7550-day 4.54200-day 4.506.2652w high52w low

19.5% under the 52-week high of 7.78 on 23 Oct 2026. 52-week low 3.10 on 18 Sep 2026. Last 15 sessions, 93.2% high to low

Volume 0.17× normal · the line is the 50-bar volume average

Profile

BOLT
52-week range, 68% of the way up
3.107.78

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Employees23
IPOFeb 05, 2021
Beta0.82
ATR, 14d0.48
Rel volume0.17
Short float2.89%
Insider own14.93%
Inst own39.40%

Snapshot

6 groups

Valuation

Index-
Market Cap12.06M
Enterprise Value15.88M
Income-28.74M
Sales4.70M
Book/sh6.56
Cash/sh9.24
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees23
IPOFeb 05, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S2.57
P/B0.95
P/C0.68
P/FCF-
EV/EBITDA-
EV/Sales3.38
Quick Ratio2.61
Current Ratio2.61
Debt/Eq1.71
LT Debt/Eq1.47
Option/ShortNo / Yes

Earnings

EPS (ttm)-16.44
EPS next Y-20.19
EPS next Q-3.69
EPS this Y-2.35%
EPS next Y-10.51%
EPS next 5Y-19.99%
EPS past 3/5Y27.67% 11.84%
Sales past 3/5Y10.33% 101.61%
EPS Y/Y TTM37.93%
Sales Y/Y TTM12.79%
EPS Q/Q-2.29%
Sales Q/Q-99.72%
EarningsAug 11 AMC
EPS/Sales Surpr.-34.94% -99.00%

Ownership

Insider Own14.93%
Insider Trans4.57%
Inst Own39.40%
Inst Trans-
ROA-49.62%
ROE-111.65%
ROIC-92.19%
Gross Margin80.45%
Oper. Margin-605.85%
Profit Margin-611.47%
SMA208.93%
SMA5037.87%
SMA20039.06%
Trades-

Technical

Shs Outstand1.93M
Shs Float1.64M
Short Float2.89%
Short Ratio0.19
Short Interest0.05M
52W High7.78 -19.54%
52W Low3.10 101.94%
Volatility6.51% 9.13%
ATR (14)0.48
RSI (14)62.97
Beta0.82
Rel Volume0.17
Avg Volume249.66K
Volume42,542

Performance

Perf Week-4.28%
Perf Month46.09%
Perf Quarter95.02%
Perf Half Y29.61%
Perf YTD14.48%
Perf Year30.15%
Perf 3Y-67.73%
Perf 5Y-96.96%
Perf 10Y-
Recom1.67
Target Price48.50
Prev Close6.30
Price6.26
Change %-0.63%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
May 29, 2026InitiatedRRodman & RenshawBuy$22+251.4%
Oct 20, 2025ResumedHH.C. WainwrightBuy$7+11.8%
Jan 06, 2022DowngradeMMorgan StanleyOverweight → Equal-Weight
Mar 02, 2021InitiatedSSVB LeerinkOutperform$36+475.1%
Mar 02, 2021InitiatedSStifelBuy$40+539.0%
Mar 02, 2021InitiatedMMorgan StanleyOverweight$45+618.8%
Mar 02, 2021InitiatedGGuggenheimBuy$42+570.9%

Peers

Mkt cap
TickerCompanyMkt cap
STROSutro Biopharma Inc170.12M
HOWLWerewolf Therapeutics Inc48.06M
PYXSPyxis Oncology Inc196.16M
CTMXCytomX Therapeutics Inc464.35M
XLOXilio Therapeutics Inc55.74M
CRBPCorbus Pharmaceuticals Holdings Inc77.36M
ZYMEZymeworks BC Inc2.02B
STTKShattuck Labs Inc514.31M
ALXOAlx Oncology Holdings Inc154.87M
CUECue Biopharma Inc135.55M

Insider trading

14 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Coastlands Capital LP10% OwnerNov 09 '26Buy6.3850,000319,000462,416Nov 10 02:57 PM
Yonehiro GrantChief Operating OfficerSep 18 '26Sale3.246,85022,16917,269Sep 21 06:05 PM
Yonehiro GrantChief Operating OfficerSep 17 '26Sale3.324,90916,29024,119Sep 21 06:05 PM
Yonehiro GrantChief Operating OfficerSep 16 '26Sale3.771,4175,34829,028Sep 21 06:05 PM
Nemec SarahSenior VP, Finance and PAOJun 05 '26Buy3.885091,9731,924Sep 21 06:04 PM
Nemec SarahSenior VP, Finance and PAOSep 18 '26Sale3.244,07713,19517,082Sep 21 06:04 PM
Nemec SarahSenior VP, Finance and PAOSep 17 '26Sale3.322,9229,69621,159Sep 21 06:04 PM
Nemec SarahSenior VP, Finance and PAOSep 16 '26Sale3.778433,18124,081Sep 21 06:04 PM
Quinn William P.President, CEO and CFOJun 05 '26Buy3.886372,4692,950Sep 21 06:03 PM
Quinn William P.President, CEO and CFOSep 18 '26Sale3.249,13229,55525,384Sep 21 06:03 PM
Quinn William P.President, CEO and CFOSep 17 '26Sale3.326,54521,71834,516Sep 21 06:03 PM
Quinn William P.President, CEO and CFOSep 16 '26Sale3.771,8897,12941,061Sep 21 06:03 PM
Quinn William P.President, CEO and CFODec 05 '25Buy4.611255762,313Feb 04 04:32 PM
Nemec SarahSenior VP, Finance and PAODec 05 '25Buy4.611255761,415Feb 04 04:32 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-11-4.570-3.387-4.5700.010.503
2026Q12026-05-12-4.310-2.850-4.3110.031.501
2025Q42026-03-12-3.840-6.107-3.8392.500.673
2025Q32025-11-12-3.720-5.676-3.7222.170.825
2025Q22025-08-14-4.460-6.300-4.4641.800.824
2025Q12025-05-12-5.800-7.100-5.7591.220.764
2024Q42025-03-24-8.400-7.600-8.3250.010.783
2024Q32024-11-12-8.000-6.800-7.9351.141.254
2024Q22024-08-13-11.200-8.760-11.1181.281.015
2024Q12024-05-14-5.600-10.200-5.6805.272.085
2023Q42024-03-21-9.400-9.400-9.4372.091.716
2023Q32023-11-09-8.600-10.000-8.5862.531.736
2023Q22023-08-07-9.600-9.534-9.5671.431.916
2023Q12023-05-11-9.000-10.000-9.0121.831.546
2022Q42023-03-29-10.600-11.734-10.6501.411.246
2022Q32022-11-10-11.600-11.066-11.6192.110.996

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY--76.066-33.5080.220.27
2021FY-59.400-62.560-52.7231.261.96
2022FY-47.200-47.166-47.1645.735.68
2023FY-36.600-34.866-36.6017.887.59
2024FY-33.000-32.267-33.0607.698.47
2025FY-17.850-21.225-17.0507.705.87
2026FY--18.270--0.00
2027FY--20.190--3.50
2028FY--30.840--8.00
2029FY--35.530--8.00
2030FY--40.090--8.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-262100.450.000.90
2026Q3S2026-10-222000.000.000.00
2026Q3S2026-09-043000.070.000.21
2026Q3S2026-08-124000.430.001.50
2026Q3S2026-08-113000.500.001.50
2026Q3S2026-05-133000.500.001.50
2026Q3S2026-03-131001.501.501.50
2026Q3S2026-01-272000.850.201.50
2026Q3S2025-11-132100.850.201.50
2026Q3S2025-11-112000.350.200.50
2026Q3S2025-11-102000.350.200.50
2026Q3S2025-11-092000.350.200.50
2026Q3S2025-11-082000.350.200.50
2026Q3S2025-11-072000.350.200.50

Estimate history

EPS, annual-6.604-17.373-33.508-52.723-47.164-36.601-33.06-17.849-16.4384
Period20182019202020212022202320242025TTM
EPS, quarterly-11.118-7.935-8.325-5.759-4.464-3.722-3.839-4.311-4.567
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00.2150.2311.265.7297.8767.697.6954.7
Period20182019202020212022202320242025TTM
Sales, quarterly1.2751.14101.2221.8042.1692.50.0260.005
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual1.7551.7551.8121.871.891.9061.9171.9211.926
Period20182019202020212022202320242025MRQ
Shares, quarterly1.9131.9141.9171.9171.9191.9191.9211.9221.926
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue4.707.707.697.885.731.260.230.210.00
Cost of Goods Sold Incl. D&A0.921.492.181.884.893.67--0.30
Gross Profit3.786.205.515.990.84-2.41---0.30
Selling, General and Administrative Excl. Other32.2640.8473.7582.1991.1690.3846.9129.8611.33
Research and Development20.5827.0455.2959.6668.2371.9837.8524.679.12
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-28.48-34.63-68.24-76.20-90.32-92.79-49.18-30.97-11.63
Interest Expense0.000.000.000.000.00--0.00-
Unusual Expense2.291.484.810.000.006.0811.740.040.15
Net Income Before Taxes-28.74-33.38-63.12-69.20-88.10-98.59-60.73-30.49-11.59
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-28.74-33.38-63.12-69.20-88.10-98.59-60.73-30.49-11.59
Net Income From Continuing Operations-28.74-33.38-63.12-69.20-88.10-98.59-60.73-30.49-11.59
Net Income-28.74-33.38-63.12-69.20-88.10-98.59-60.73-30.49-11.59
EPS (Recurring)-16.05-17.29-31.30-36.60-47.16-50.45-28.97-17.36-6.54
EPS (Basic, Before Extraordinaries)-16.44-17.85-33.06-36.60-47.16-52.72-33.51-17.37-6.60
EPS (Diluted)-16.44-17.85-33.06-36.60-47.16-52.72-33.51-17.37-6.60
EBITDA-27.56-33.14-66.06-74.31-85.43-89.12-46.68-29.64-11.33
Non-Operating Income (Expense)2.022.749.937.002.220.280.200.520.19
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.542.787.419.229.588.501.420.510.12
Price To Sales Ratio1.381.332.665.388.48145.44---
Gross Margin80.4580.6271.6476.0814.63-191.43---
Operating Margin-605.85-450.07-887.33-967.45-1,576.56-7,364.13-21,290.91-14,404.19-
Net Margin-611.47-433.74-820.78-878.58-1,537.76-7,824.68-26,289.18-14,180.00-
Shares Outstanding1.931.921.921.911.891.871.811.751.75
Market Capitalization12.1412.1420.5242.5248.96183.26184.01--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.010.032.502.171.801.220.001.14
Cost of Goods Sold Incl. D&A0.170.200.260.290.350.400.430.44
Gross Profit-0.17-0.182.251.881.460.82-0.430.70
Selling, General and Administrative Excl. Other7.407.427.859.5810.6712.9415.2417.14
Research and Development4.984.634.736.257.159.1111.3013.35
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.57-7.60-5.61-7.70-9.21-12.12-15.67-16.44
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.810.001.480.000.000.001.250.00
Net Income Before Taxes-7.72-7.24-6.63-7.14-8.56-11.04-15.94-15.18
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-7.72-7.24-6.63-7.14-8.56-11.04-15.94-15.18
Net Income From Continuing Operations-7.72-7.24-6.63-7.14-8.56-11.04-15.94-15.18
Net Income-7.72-7.24-6.63-7.14-8.56-11.04-15.94-15.18
EPS (Recurring)-4.23-4.31-3.24-3.72-4.46-5.76-7.87-7.93
EPS (Basic, Before Extraordinaries)-4.57-4.31-3.84-3.72-4.46-5.76-8.32-7.93
EPS (Diluted)-4.57-4.31-3.84-3.72-4.46-5.76-8.32-7.93
EBITDA-7.39-7.40-5.35-7.41-8.86-11.72-15.24-16.00
Non-Operating Income (Expense)0.650.360.450.560.651.070.981.27
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.550.551.040.410.620.711.181.10
Price To Sales Ratio1.381.041.231.972.664.222.662.53
Gross Margin-3,320.00-680.7789.8086.6380.7667.35-61.44
Operating Margin-151,320.00-29,234.62-224.20-355.14-510.53-991.41--1,441.10
Net Margin-154,400.00-27,861.54-265.24-329.37-474.56-903.44--1,330.06
Shares Outstanding1.931.921.921.921.921.921.921.91
Market Capitalization12.147.7610.5010.2111.0615.3420.5224.80

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments27.7048.11102.19168.89186.2222.8434.8313.63
Short Term Receivables0.971.171.300.800.200.010.300.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets1.411.492.043.062.742.510.770.47
Total Current Assets30.0950.76105.53172.75189.1625.3635.9014.10
Net Property, Plant & Equipment20.4824.8924.0828.5230.6016.3811.521.44
Total Investments and Advances5.8823.8628.1825.5186.911.560.580.00
Deferred Tax Assets5.66-------
Other Assets0.310.122.001.031.043.230.450.43
Total Assets62.4099.63159.78227.81307.7246.5448.4515.97
Short Term Debt Incl. Current Port. of LT Debt2.832.252.782.392.501.503.100.04
Accounts Payable1.441.512.993.593.571.602.100.89
Other Current Liabilities4.1712.1014.6917.1315.258.163.461.82
Total Current Liabilities8.4415.8620.4623.1221.3311.268.662.75
Long Term Debt20.1322.9617.4420.2221.8534.607.090.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities5.66-------
Other Liabilities1.683.629.1512.9614.420.331.040.80
Total Liabilities35.9042.4347.0456.3057.6046.1916.793.55
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00105.3077.5028.37
Common Equity26.5057.20112.74171.51250.12-104.95-45.85-15.94
Total Shareholders Equity26.5057.20112.74171.51250.120.3531.6612.42
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity26.5057.20112.74171.51250.120.3531.6612.42
Total Liabilities & Stockholders Equity62.4099.63159.78227.81307.7246.5448.4515.97
Book Value Per Share13.8029.8459.1690.75133.75-57.91-26.13-9.09
Tangible Book Value Per Share13.8029.8459.1690.75133.75-57.91-26.13-9.09
Full-Time Employees2352100949165--
Price to Book Ratio0.960.360.330.260.730.67--
Return on Assets-41.20-48.66-35.71-32.90-55.66-127.86-94.65-
Return on Equity-79.75-74.28-48.69-41.79-78.73-379.46-138.32-
Return on Invested Capital-71.57-78.74-53.16-45.95-36.25-173.76-78.68-93.28
Quick Ratio3.573.205.167.478.872.254.155.12
Current Ratio3.573.205.167.478.872.254.155.12

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-28.74-33.38-63.12-69.20-88.10-98.59-60.73-30.49-11.59
Depreciation0.921.291.781.854.893.672.501.330.30
Other Funds (Non Cash)5.174.358.497.689.7617.3513.200.550.28
Funds from Operations-22.65-27.73-52.85-59.66-73.45-77.57-45.02-28.61-11.01
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-8.80-12.12-8.44-9.86-3.0620.51-2.282.271.14
Cash from Operating Activities-31.45-39.85-61.29-69.53-76.50-57.07-47.31-26.34-9.87
Capital Expenditures0.00-0.07-0.04-0.21-1.95-2.34-3.26-0.51-0.29
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.720.960.150.000.000.000.000.000.00
Purchase or Sale of Investments34.0243.4157.4771.2459.81-229.86-17.330.000.00
Purchase of Investments-14.79-29.02-88.86-164.99-180.70-313.38-33.230.000.00
Sale Or Maturity of Investments48.8172.43146.32236.23240.5283.5115.900.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities34.6544.3057.5871.0457.86-232.20-20.59-0.51-0.29
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.040.020.110.250.50311.1139.6048.6719.13
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.040.020.110.250.50311.1139.6048.6719.13
Proceedsfrom Stock Options0.040.020.110.250.50311.1139.3048.6719.13
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00-0.04-0.04
Change in Long Term Debt0.000.000.000.000.000.000.00-0.04-0.04
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00-0.04-0.04
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities0.030.020.110.250.50311.1139.6048.6319.09
Net Change in Cash3.234.47-3.601.77-18.1421.84-28.3021.788.93
Free Cash Flow--39.92-61.33-69.73-78.46-59.40-50.57-26.85-10.16
Preferred Dividends (Cash Flow)-0.000.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments17.8023.0927.7032.6935.5539.62
Short Term Receivables0.000.000.970.950.700.71
Inventories0.000.000.000.000.000.00
Other Current Assets2.772.661.411.962.082.18
Total Current Assets20.5625.7530.0935.6138.3442.51
Net Property, Plant & Equipment17.6519.6120.4821.3822.2323.21
Total Investments and Advances2.052.565.887.8914.7120.10
Deferred Tax Assets--5.66---
Other Assets0.090.110.310.180.220.05
Total Assets40.3448.0362.4065.0575.5085.86
Short Term Debt Incl. Current Port. of LT Debt3.092.962.832.702.562.40
Accounts Payable0.871.741.441.521.851.53
Other Current Liabilities3.912.654.175.757.909.63
Total Current Liabilities7.877.348.449.9712.3113.56
Long Term Debt18.5319.3520.1320.8921.6222.31
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--5.66---
Other Liabilities1.301.511.682.102.723.18
Total Liabilities27.7028.2035.9032.9536.6639.05
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity12.6419.8226.5032.1038.8446.81
Total Shareholders Equity12.6419.8226.5032.1038.8446.81
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity12.6419.8226.5032.1038.8446.81
Total Liabilities & Stockholders Equity40.3448.0362.4065.0575.5085.86
Book Value Per Share6.5610.3213.8016.7220.2424.42
Tangible Book Value Per Share6.5610.3213.8016.7220.2424.42
Full-Time Employees--23---
Price to Book Ratio0.960.290.330.260.240.33
Return on Assets-49.62-44.19-41.20-48.95-50.80-55.38
Return on Equity-111.65-88.79-79.75-81.97-81.33-83.92
Return on Invested Capital-24.77-18.49-14.22-13.48-14.16-15.97
Quick Ratio2.613.513.573.573.113.13
Current Ratio2.613.513.573.573.113.13

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-7.72-7.24-6.63-7.14-8.56-11.04
Depreciation0.170.200.260.290.350.40
Other Funds (Non Cash)1.591.141.530.911.080.83
Funds from Operations-5.96-5.91-4.84-5.94-7.13-9.81
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.58-2.12-2.31-3.79-2.46-3.55
Cash from Operating Activities-6.54-8.02-7.16-9.73-9.60-13.37
Capital Expenditures0.000.000.00-0.070.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.690.030.000.000.000.96
Purchase or Sale of Investments7.107.891.0717.9610.7913.59
Purchase of Investments0.00-1.23-11.84-1.72-14.46-0.99
Sale Or Maturity of Investments7.109.1212.9119.6825.2614.58
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities7.777.921.0717.8810.7914.55
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.020.010.010.010.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.020.010.010.010.000.00
Proceedsfrom Stock Options0.020.010.010.010.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.020.010.010.000.010.00
Net Change in Cash1.25-0.09-6.088.151.211.19
Free Cash Flow---7.16-9.80-9.60-13.37

Revenue breakdown

Pharmaceutical Preparations2024: 7.69M 2025: 7.70M
United States2024: 7.69M 2025: 7.70M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.89%0.0M1.6M240.53K
2026-10-150.96%0.0M1.6M27.15K
2026-09-301.57%0.0M1.6M25.79K
2026-09-151.13%0.0M1.6M25.06K
2026-08-310.95%0.0M1.6M24.17K
2026-08-140.05%0.0M1.6M26.81K
2026-07-310.24%0.0M1.6M25.17K
2026-07-150.37%0.0M1.6M28.99K
2026-06-301.06%0.0M1.6M29.57K
2026-06-151.74%0.0M1.6M25.80K
2026-05-290.84%0.0M1.6M24.54K
2026-05-150.77%0.0M1.6M24.47K
2026-04-300.45%0.0M1.6M26.16K
2026-04-151.46%0.0M1.6M24.39K
2026-03-310.33%0.0M1.5M24.92K
2026-03-130.06%0.0M1.5M27.69K
2026-02-270.12%0.0M1.5M38.97K
2026-02-130.04%0.0M1.5M39.34K
2026-01-300.12%0.0M1.3M39.10K
2026-01-150.19%0.0M1.3M38.82K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-09SEC
2026-11-063Initial statement of beneficial ownership of securities2026-11-06SEC
2026-11-06SCHEDULE 13GSEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-273Initial statement of beneficial ownership of securities2026-10-23SEC
2026-10-238-KCurrent report2026-10-23SEC
2026-10-068-KCurrent report2026-10-01SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-08-13SCHEDULE 13GSEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-118-KCurrent report2026-06-11SEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-04-28ARSAnnual report to security holders. 2025-12-31SEC
2026-04-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-27SEC
2026-03-12S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-1210-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-128-KCurrent report2026-03-12SEC
2026-02-26SCHEDULE 13D/ASEC
2026-02-17SCHEDULE 13D/ASEC
2026-02-13SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11319.00K100
2026-100000
2026-0900128.28K9
2026-080000
2026-070000
2026-064.44K200
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-121.15K200
2025-110000

Institutional holders

Manager% owned
Sofinnova Investments, Inc.7.17%
RENAISSANCE TECHNOLOGIES LLC5.13%
Vivo Capital, LLC3.77%
CITADEL ADVISORS LLC2.96%
T3 Companies, LLC1.97%
Board of Trustees of The Leland Stanford Junior University1.87%
PFIZER INC1.63%
Lynx1 Capital Management LP1.60%
NANO CAP NEW MILLENNIUM GROWTH FUND L P1.43%
GEODE CAPITAL MANAGEMENT, LLC0.82%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.39%
VANGUARD EXTENDED MARKET INDEX FUND0.37%
Fidelity Total Market Index Fund0.28%
Fidelity Series Total Market Index Fund0.09%
Fidelity Nasdaq Composite Index Fund0.01%
Diversified Equity Alpha Master Portfolio0.00%
Guggenheim Active Allocation Fund0.00%

OakChart. BOLT. Cached 15 minutes.